WHO strongly advises against two antibody therapies for Covid-19

There are a handful of existing Covid therapeutics that remain useful in the fight against the virus, and others in development that are expected to also benefit patients.

Two Covid-19 antibody therapies are no longer recommended by the World Health Organization (WHO), on the basis that Omicron and the variant's latest offshoots have likely rendered them obsolete.

The two therapies - which are designed to work by binding to the spike protein of SARS-CoV-2 to neutralise the virus' ability to infect cells - were some of the first medicines developed early in the pandemic.